课题基金 / 基金详情

URSODIOL-METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS

URSODIOL-METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS
熊二醇-甲氨蝶呤治疗原发性胆汁性肝硬化
批准号:
2766723
负责人:
BURTON COMBES
金额:
$86.94万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-04-01 至 2004-03-31

项目摘要

项目成果

BURTON COMBES的其他基金

相似基金

相关文献

中文摘要
翻译
这项随机双盲临床试验的主要目的是 确定原发性胆道疾病患者的治疗 肝硬化(PBC)与熊去氧胆酸(熊去氧胆酸-UDCA)加 甲氨蝶呤(MTX)比单用UDCA治疗更有效。 PBC是一种慢性胆汁淤积性肝病,主要发生于女性, 小叶间和隔胆管发生炎症, 杀伤性 一旦开始,疾病持续存在并进展至 不同的利率。 无论是启动机制还是延续机制, 很好理解。目前发病机制的概念包括(1) 胆管的破坏被维持,并且可能是由以下因素引起的: 自身免疫机制;(2)疏水性胆汁酸, 血清和肝脏引起功能性和细胞毒性肝损伤;(3) 在炎症部位释放的细胞因子和淋巴因子可 导致细胞损伤和纤维化。 大量证据表明 表明口服UDCA可改善肝脏检查, 瘙痒症和肝组织学。 意见上存在分歧 至于是否发展为肝脏疾病的并发症,肝脏 移植或无移植存活受到影响。 UDCA a 相对无毒的胆汁酸,当口服给药时, 胆汁酸合并液的组成(以UDCA富集系数计) 并且似乎可以防止内源性胆汁的细胞毒性作用 由于胆管破坏而积聚的酸。 mtx是 被证明可以改善肝脏测试,症状和肝脏组织学, 少数PBC患者的预后。 的作用机制 未知,但认为与抗炎-免疫抑制相关 MTX的作用 目前的试验探讨MTX是否能改善 UDCA在PBC中的治疗作用。PBC患者血清 胆红素低于3 mg %,接受UDCA至少 6个月,并且符合一系列入选和排除标准 根据肝组织学分期分为2组 (路德维希分类),即早期(I期或II期)与晚期( III或IV)。 然后他们被随机接受甲氨蝶呤或 安慰剂作为第二种药物,同时继续接受UDCA。 的 通过比较两个治疗组的相对值, 对症状的影响,实验室检查结果, 肝脏疾病的并发症,肝脏的组织学变化,肝脏 移植和无移植存活率。 每个人的安全 治疗方案也正在确定中。
英文摘要
The major thrust of this randomized, double-blinded clinical trial is to determine whether treatment of patients with Primary Biliary Cirrhosis (PBC) with Ursodiol (Ursodeoxycholic Acid-UDCA) plus methotrexate (MTX) is more effective than treatment with UDCA alone. PBC is a chronic cholestatic liver disease, predominantly of women, in which interlobular and septal bile ducts undergo inflammation and destruction. Once initiated, the disease persists and progresses at varying rates. Neither the initiating nor perpetuating mechanisms are well understood. Current concepts of pathogenesis include (1) destruction of bile ducts is maintained and perhaps initiated by autoimmune mechanisms; (2) hydrophobic bile acids which accumulate in serum and liver cause functional and cytotoxic liver injury; (3) cytokines and lymphokines released at sites of inflammation may contribute to cell damage and fibrosis. A considerable body of evidence indicates that UDCA when fed orally leads to improvement in liver tests, in pruritus and in liver histology. There exist differences in opinion as to whether development of complications of liver disease, liver transplantation or transplant-free survival is affected. UDCA a relatively non-toxic bile acid, when administered orally, alters the composition of the bile acid pool in factor of its enrichment with UDCA and appears to protect against the cytotoxic effects of endogenous bile acids that accumulate as a result of bile duct destruction. MTX is being shown to improve liver tests, symptoms and liver histology in a small number of precirrhotic patients with PBC. The mechanism of action is unknown but felt to be related to antiinflammatory-immunosuppressive effects of MTX. The current trial explores whether MTX improves the therapeutic effects of UDCA in PBC. Patients with PBC whose serum bilirubin is less than 3 mg percent, who have been on UDCA for at least 6 months, and who satisfy a series of inclusion and exclusion criteria are stratified into 2 groups on the basis of liver histologic stage (Ludwig classification), i.e. early (Stages I or II) versus late (Stages III or IV). They are then randomized to receive either methotrexate or its placebo as a second drug while continuing to receive UDCA. The relative value of the two treatment arms is assessed by comparing their effects on symptoms, results of laboratory tests, development of complications of liver disease, histologic changes in liver, liver transplantation, and on transplant-free survival. The safety of each therapeutic regimen is also being determined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
URSODEOXYCHOLIC ACID (UDCA) IN PRIMARY BILIARY CIRRHOSIS
  • 批准号:
    7377595
  • 项目类别:
  • 资助金额:
    $0.27万
  • 财政年份:
    2006
  • 负责人:
    BURTON COMBES
  • 依托单位:
URSODEOXYCHOLIC ACID (UDCA) IN PRIMARY BILIARY CIRRHOSIS
  • 批准号:
    7205991
  • 项目类别:
  • 资助金额:
    $0.39万
  • 财政年份:
    2005
  • 负责人:
    BURTON COMBES
  • 依托单位:
UDCA & METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS
  • 批准号:
    7205992
  • 项目类别:
  • 资助金额:
    $3.68万
  • 财政年份:
    2005
  • 负责人:
    BURTON COMBES
  • 依托单位:
UDCA & Methotrexate for Primary Biliary Cirrhosis
  • 批准号:
    6975038
  • 项目类别:
  • 资助金额:
    $5.56万
  • 财政年份:
    2004
  • 负责人:
    BURTON COMBES
  • 依托单位:
海外基金